GUIDED THERAPEUTICS Reports Widening Q1 Loss, Reiterates Going Concern Warning Amid Heavy Dilution
GTHP has more than doubled off its 52-week low of $0.064.
Summary
Guided Therapeutics reported a substantially wider net loss in Q1 2026, reiterated its going concern warning, and continues to rely on dilutive financing to fund operations, despite ongoing material weaknesses in financial controls.
Key Events · Earnings and Guidance · GTHP
-
Net Loss More Than Doubled
Net loss attributable to common stockholders increased to $1.013 million for Q1 2026, up from $463,000 in Q1 2025, indicating worsening financial performance.
-
Going Concern Warning Reiterated
The company continues to operate under a going concern warning, with a working capital deficit of $5.1 million and an accumulated deficit of $158.0 million as of March 31, 2026, raising substantial doubt about its ability to continue operations.
-
Significant Dilution from Financing Activities
Common shares outstanding increased by over 10.35 million in Q1 2026. The company raised $980,000 from warrant exercises, but outstanding convertible instruments represent potential dilution of approximately 45.55 million common shares.
-
Critical Funding Gap
Despite a cash increase to $369,000, the company estimates needing $2.4 million to fund operations over the next 12 months, highlighting a significant funding shortfall.
Analysis · GTHP · Industrial Applications And Services
Guided Therapeutics continues to face severe financial challenges, as evidenced by a significantly increased net loss and a reiterated going concern warning. The company's cash position remains critically low relative to its funding needs, forcing reliance on highly dilutive financing activities. Ongoing material weaknesses in financial controls add to the operational risks, making the path to sustained operations highly uncertain.
At the time of this filing, GTHP was trading at $0.20 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $19.3M. The 52-week trading range was $0.06 to $0.54. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.